STING1 and neoplasm: Furthermore, treatment of Hepa 1–6 tumor-bearing mice with the STING inhibitor C-176 impaired the antitumor efficacy of triple therapy (482.4±72.9 (triple therapy plus STING inhibitor) vs 80.5±31.4 (triple therapy), p<0.0001; vs 265.2±27.4 (radioimmunotherapy), p=0.0003) (figure 6B).